TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myofascial Release Therapy in the Treatment of Occupational Mechanical Neck Pain: a Randomized Parallel Group Study.
Brief Summary: Mechanical neck pain is a musculoskeletal disorder usually associated with work absenteeism. Myofascial release therapy (MRT) is currently under development and has the treatment of mechanical neck pain as one of its main focal points. However, there is a paucity of studies reporting its effectiveness. For that purpose a randomized single-blind parallel group study was designed to compare the effectiveness of MRT with manual therapy (MT) for treating occupational mechanical neck pain. The sample (n=59) was randomly assigned to two therapeutic intervention programs. Group I patients were treated with MT and Group II patients were treated with MRT. Variables studied were intensity of neck pain, cervical disability, quality of life (QoL), craniovertebral angle and ranges of cervical motion.


Options:
A: Arm Label: Manual Therapy + Analgesic therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual Therapy, Device: Analgesic therapy | Arm Label: Myofascial Release + Analgesic therapy; Type: EXPERIMENTAL; Interventions: Other: Myofascial Release Therapy, Device: Analgesic therapy | Intervention Type: OTHER; Name: Manual Therapy; Assigned to Arm(s): Manual Therapy + Analgesic therapy | Intervention Type: OTHER; Name: Myofascial Release Therapy; Assigned to Arm(s): Myofascial Release + Analgesic therapy | Intervention Type: DEVICE; Name: Analgesic therapy; Assigned to Arm(s): Manual Therapy + Analgesic therapy, Myofascial Release + Analgesic therapy
B: Arm Label: Massage Dose 1; Type: EXPERIMENTAL; Interventions: Other: Massage | Arm Label: Massage - Dose 2; Type: EXPERIMENTAL; Interventions: Other: Massage | Arm Label: Massage - Dose 3; Type: EXPERIMENTAL; Interventions: Other: Massage | Arm Label: Massage - Dose 4; Type: EXPERIMENTAL; Interventions: Other: Massage | Arm Label: Massage - Dose 5; Type: EXPERIMENTAL; Interventions: Other: Massage | Arm Label: Massage - Dose 6; Type: EXPERIMENTAL; Interventions: Other: Massage | Intervention Type: OTHER; Name: Massage; Assigned to Arm(s): Massage - Dose 2, Massage - Dose 3, Massage - Dose 4, Massage - Dose 5, Massage - Dose 6, Massage Dose 1
C: Arm Label: Dry needling; Type: EXPERIMENTAL; Interventions: Other: Dry Needling | Arm Label: Ischemic compression; Type: EXPERIMENTAL; Interventions: Other: Ischemic Compression | Intervention Type: OTHER; Name: Dry Needling; Assigned to Arm(s): Dry needling | Intervention Type: OTHER; Name: Ischemic Compression; Assigned to Arm(s): Ischemic compression
D: Arm Label: Post Isometric Relaxation; Type: EXPERIMENTAL; Interventions: Other: 1.Post Isometric Relaxation | Arm Label: Myofascial Release Therapy; Type: EXPERIMENTAL; Interventions: Other: 1.Myofascial Release therapy | Intervention Type: OTHER; Name: 1.Post Isometric Relaxation; Assigned to Arm(s): Post Isometric Relaxation | Intervention Type: OTHER; Name: 1.Myofascial Release therapy; Assigned to Arm(s): Myofascial Release Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial)
Brief Summary: The primary objective of this trial is to assess the safety of an uninterrupted dabigatran etexilate periprocedural anticoagulant regimen compared to an uninterrupted warfarin regimen in Non-Valvular Atrial Fibrillation (NVAF) patients undergoing Atrial Fibrillation (AF) ablation in a PROBE (Prospective, randomized, open label, blinded end point) active controlled study.

Secondary objectives are to assess additional safety endpoints and efficacy in this clinical setting.

It is not intended to assess confirmatory hypothesis, this is an exploratory study.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Arm 4
B: Arm Label: Dabigatran Etexilate 150mg; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran Etexilate 150mg | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran Etexilate 150mg; Assigned to Arm(s): Dabigatran Etexilate 150mg
C: Arm Label: BAY59-7939; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Standard of Care; Type: EXPERIMENTAL; Interventions: Drug: Standard of Care | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): BAY59-7939 | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): BAY59-7939 | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: Low-molecular-weight heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Low-molecular-weight heparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mobile Health Intervention to Improve Perinatal Continuum of Care in Guatemala
Brief Summary: The purpose of the study is to explore ways to improve maternal and child outcomes in the ethnic Maya speaking the Kaqchikel language population, which experiences wide disparities in health care access and outcomes when compared to other inhabitants of Guatemala who are not ethnically Maya and live in other parts of the country.


Options:
A: Arm Label: mHealth midwives; Type: EXPERIMENTAL; Interventions: Device: mHealth | Arm Label: mHealth midwives - control; Type: ACTIVE_COMPARATOR; Interventions: Device: mHealth | Arm Label: Pregnant Women; Type: ACTIVE_COMPARATOR; Interventions: Device: mHealth | Intervention Type: DEVICE; Name: mHealth; Assigned to Arm(s): Pregnant Women, mHealth midwives, mHealth midwives - control
B: Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: evaluation of cancer risk factors; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fecal occult blood test; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: screening colonoscopy; Assigned to Arm(s): N/A
C: Arm Label: Arm 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Osteoarthritis Intervention | Intervention Type: BEHAVIORAL; Name: Osteoarthritis Intervention; Assigned to Arm(s): Arm 2
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: computer-based decision support for asthma management | Intervention Type: DEVICE; Name: computer-based decision support for asthma management; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mobile Health Intervention to Improve Perinatal Continuum of Care in Guatemala
Brief Summary: The purpose of the study is to explore ways to improve maternal and child outcomes in the ethnic Maya speaking the Kaqchikel language population, which experiences wide disparities in health care access and outcomes when compared to other inhabitants of Guatemala who are not ethnically Maya and live in other parts of the country.


Options:
A: Arm Label: mHealth midwives; Type: EXPERIMENTAL; Interventions: Device: mHealth | Arm Label: mHealth midwives - control; Type: ACTIVE_COMPARATOR; Interventions: Device: mHealth | Arm Label: Pregnant Women; Type: ACTIVE_COMPARATOR; Interventions: Device: mHealth | Intervention Type: DEVICE; Name: mHealth; Assigned to Arm(s): Pregnant Women, mHealth midwives, mHealth midwives - control
B: Arm Label: Multi-modal practice intervention; Type: N/A; Interventions: Behavioral: HeartAge intervention | Arm Label: Usual care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: HeartAge intervention; Assigned to Arm(s): Multi-modal practice intervention
C: Arm Label: A - coded unit ID; Type: EXPERIMENTAL; Interventions: Other: clinical decision support | Arm Label: B - coded unit ID; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: clinical decision support; Assigned to Arm(s): A - coded unit ID
D: Arm Label: Intervention; Type: OTHER; Interventions: Behavioral: Vascular Management Program, Behavioral: Clinical Care Coordinators, Behavioral: Web-based Vascular Tracker for Patient and Physician, Behavioral: Automated Telephone Reminder System | Intervention Type: BEHAVIORAL; Name: Vascular Management Program; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Clinical Care Coordinators; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Web-based Vascular Tracker for Patient and Physician; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Automated Telephone Reminder System; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Brief Summary: The study intervention consists of the early integration of palliative care services into standard oncology care in an outpatient setting for patients with advanced lung and non-colorectal gastrointestinal malignancies who are not being treated with curative intent. The palliative care services provided to patients randomized to the intervention will be provided by board-certified physicians and/or advanced practice nurses and will focus on the following areas: (1) developing and maintaining the therapeutic relationship with the patients and family caregivers; (2) assessing and treating patient symptoms; (3) providing support and reinforcement of coping with advanced cancer in patients and family caregivers; (4) assessing and enhancing prognostic awareness and illness understanding in patients and family caregivers; (5) assisting with treatment decision-making; and (6) end-of-life care planning.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Early palliative care | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Other: Early palliative care | Intervention Type: OTHER; Name: Early palliative care; Assigned to Arm(s): Arm 1, Arm 2
B: Arm Label: Methylphenidate add on to Mirtazapine; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Placebo add on to Mirtazapine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate add on to Mirtazapine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo add on to Mirtazapine
C: Arm Label: Psilocybin; Type: EXPERIMENTAL; Interventions: Drug: Psilocybin, Drug: Niacin | Arm Label: Niacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Psilocybin, Drug: Niacin | Intervention Type: DRUG; Name: Psilocybin; Assigned to Arm(s): Niacin, Psilocybin | Intervention Type: DRUG; Name: Niacin; Assigned to Arm(s): Niacin, Psilocybin
D: Arm Label: Arm I (management of therapy complications); Type: EXPERIMENTAL; Interventions: Drug: venlafaxine, Other: questionnaire administration, Other: quality-of-life assessment | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Other: questionnaire administration, Other: quality-of-life assessment | Intervention Type: DRUG; Name: venlafaxine; Assigned to Arm(s): Arm I (management of therapy complications) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm II (placebo) | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): Arm I (management of therapy complications), Arm II (placebo) | Intervention Type: OTHER; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (management of therapy complications), Arm II (placebo)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Genetically Informed Smoking Cessation Trial
Brief Summary: The investigators' goal is to identify the most appropriate smoking cessation treatments for smokers based on genetic information. Smokers try to quit smoking but relapses are common.


Options:
A: Arm Label: Augmented Treatment; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Behavioral Counseling Sessions, Drug: NicodermCQ | Arm Label: Standard Treatment w/ placebo; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Counseling Sessions, Drug: NicodermCQ, Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Augmented Treatment | Intervention Type: BEHAVIORAL; Name: Behavioral Counseling Sessions; Assigned to Arm(s): Augmented Treatment, Standard Treatment w/ placebo | Intervention Type: DRUG; Name: NicodermCQ; Assigned to Arm(s): Augmented Treatment, Standard Treatment w/ placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard Treatment w/ placebo
B: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Combination NRT and Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combination NRT (Nicotine patch, Nicotine lozenge), Behavioral: Intensive smoking counseling | Arm Label: Varenicline (Chantix) and Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Intensive smoking counseling | Arm Label: Placebo Medicine and Counseling; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Intensive smoking counseling | Intervention Type: DRUG; Name: Combination NRT (Nicotine patch, Nicotine lozenge); Assigned to Arm(s): Combination NRT and Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (Chantix) and Counseling | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Medicine and Counseling | Intervention Type: BEHAVIORAL; Name: Intensive smoking counseling; Assigned to Arm(s): Combination NRT and Counseling, Placebo Medicine and Counseling, Varenicline (Chantix) and Counseling

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of the Impact of Offering a Nutrition and Health Intervention to Children Recovered From Moderate Acute Malnutrition
Brief Summary: Children who recover from moderate acute malnutrition in Malawi remain at high risk for relapse or death in the year following recovery. This cluster-randomized trial will evaluate a package of affordable, safe, proven interventions specifically targeted to this population of children in an attempt to decrease their risk of relapse or death following recovery from moderate acute malnutrition. These children will be followed for a year following recovery to assess rates of relapse and mortality.


Options:
A: Arm Label: No Intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Package of interventions; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lipid Nutrient Supplement, Drug: Sulfadoxine-pyrimethamine, Drug: Albendazole, Drug: Zinc, Other: Insecticide-treated bednet | Intervention Type: DIETARY_SUPPLEMENT; Name: Lipid Nutrient Supplement; Assigned to Arm(s): Package of interventions | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine; Assigned to Arm(s): Package of interventions | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Package of interventions | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Package of interventions | Intervention Type: OTHER; Name: Insecticide-treated bednet; Assigned to Arm(s): Package of interventions
B: Arm Label: Albendazole; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Deworming at 12 months of age; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole, Other: Usual care | Arm Label: Deworming at 18 months of age; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole, Other: Usual care | Arm Label: Deworming at 12 and 18 months of age; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole, Other: Usual care | Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: DRUG; Name: Mebendazole; Assigned to Arm(s): Deworming at 12 and 18 months of age, Deworming at 12 months of age, Deworming at 18 months of age | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Deworming at 12 and 18 months of age, Deworming at 12 months of age, Deworming at 18 months of age, Usual care
D: Arm Label: Alternative SoF; Type: EXPERIMENTAL; Interventions: Other: Alternative summary of findings table format | Arm Label: Current SoF; Type: ACTIVE_COMPARATOR; Interventions: Other: Current summary of findings table format | Intervention Type: OTHER; Name: Alternative summary of findings table format; Assigned to Arm(s): Alternative SoF | Intervention Type: OTHER; Name: Current summary of findings table format; Assigned to Arm(s): Current SoF

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
Brief Summary: A randomized, double-blind, placebo-controlled intervention trial involving 100 treated subjects undergoing endonasal trans-sphenoidal (ENTS) resection of pituitary lesion. Subjects will be randomized into two groups: 50 treated in the opioid-sparing arm and 50 treated in the standard post-operative medication arm.


Options:
A: Arm Label: ibuprofen( 400mg group); Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: ibuprofen( 800mg group); Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen( 400mg group), ibuprofen( 800mg group) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo group
B: Arm Label: Maxigesic IV; Type: EXPERIMENTAL; Interventions: Drug: Maxigesic IV | Arm Label: IV Acetaminophen; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Acetaminophen | Arm Label: IV Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Ibuprofen | Arm Label: Placebo IV; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV | Intervention Type: DRUG; Name: Maxigesic IV; Assigned to Arm(s): Maxigesic IV | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen | Intervention Type: DRUG; Name: IV Ibuprofen; Assigned to Arm(s): IV Ibuprofen | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): Placebo IV
C: Arm Label: intravenous ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous ibuprofen | Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal saline as placebo comparator | Intervention Type: OTHER; Name: Normal saline as placebo comparator; Assigned to Arm(s): normal saline | Intervention Type: DRUG; Name: Intravenous ibuprofen; Assigned to Arm(s): intravenous ibuprofen
D: Arm Label: IV Caldolor (ibuprofen); Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Caldolor | Arm Label: standard treatment group; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo | Intervention Type: DRUG; Name: IV Caldolor; Assigned to Arm(s): IV Caldolor (ibuprofen) | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): standard treatment group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
Brief Summary: A randomized, double-blind, placebo-controlled intervention trial involving 100 treated subjects undergoing endonasal trans-sphenoidal (ENTS) resection of pituitary lesion. Subjects will be randomized into two groups: 50 treated in the opioid-sparing arm and 50 treated in the standard post-operative medication arm.


Options:
A: Arm Label: IV Caldolor (ibuprofen); Type: ACTIVE_COMPARATOR; Interventions: Drug: IV Caldolor | Arm Label: standard treatment group; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo | Intervention Type: DRUG; Name: IV Caldolor; Assigned to Arm(s): IV Caldolor (ibuprofen) | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): standard treatment group
B: Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous acetaminophen | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for IV acetaminophen | Intervention Type: DRUG; Name: Intravenous acetaminophen; Assigned to Arm(s): Intervention group | Intervention Type: DRUG; Name: Placebo for IV acetaminophen; Assigned to Arm(s): Placebo Group
C: Arm Label: Sumatriptan; Type: EXPERIMENTAL; Interventions: Drug: Sumatriptan, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sumatriptan, Other: Placebo | Intervention Type: DRUG; Name: Sumatriptan; Assigned to Arm(s): Placebo, Sumatriptan | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo, Sumatriptan
D: Arm Label: Morphine 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Morphine | Arm Label: Morphine 0.5; Type: EXPERIMENTAL; Interventions: Drug: Morphine | Arm Label: Dexketoprofen & Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexketoprofen, Drug: Placebo | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine 0.5, Morphine 1 mg | Intervention Type: DRUG; Name: Dexketoprofen; Assigned to Arm(s): Dexketoprofen & Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dexketoprofen & Placebo

Answer: A